MedPath

The effect, safety and money saving difference between two blood pressure medicines olmesartan and telmisartan.

Phase 4
Conditions
Health Condition 1: I10- Essential (primary) hypertension
Registration Number
CTRI/2023/10/058698
Lead Sponsor
ESIC Medical College and Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Adult patients aged 18 years or older

2.Patients who are newly diagnosed with hypertension.

3.Patients of either gender.

Exclusion Criteria

1.Patients receiving any other antihypertensive medication, corticosteroids and immunosuppressive agents

2.Patient with history of renal disease.

3.Pregnant and lactating women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To compare the cost-effectiveness of olmesartan & telmisartan on reducing blood pressure. <br/ ><br>2.To compare the effect of olmesartan & telmisartan on blood pressure in newly diagnosed hypertensive patients. <br/ ><br>3.To compare the tolerability of olmesartan and telmisartanTimepoint: 1.Blood pressure will be assessed at baseline,2nd week,4th week,8th week,12th week. <br/ ><br>2.tolerability is checked by adverse effects profile at baseline and at 12th week <br/ ><br>3.cost-effectiveness assessed by ICER ratio at 12th week. <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
To evaluate & compare the effect of olmesartan & telmisartan on fasting lipid profile, fasting blood sugar & renal function(serum creatinine). <br/ ><br>Timepoint: The percentage reduction of fasting blood sugar, fasting lipid profile & renal function(serum creatinine) by 10% of the base line value. <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath